Structure Therapeutics Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect the Board’s three nominees for Class III director to hold office until the 2029 Annual General Meeting.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

   More detail

   The Audit Committee seeks shareholder ratification of its selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026, a routine practice though not required. The proposal asks shareholders to ratify EY’s appointment to continue audit services; management frames this as good corporate practice and emphasizes EY’s tenure since 2023 and Audit Committee oversight of independence and fees. The accompanying disclosure provides fee levels for audit and tax services in 2024 and 2025 and describes Audit Committee pre-approval policies, independence determinations and the committee’s authority to replace EY if shareholders do not ratify or if it believes a change is in shareholders’ best interests. The board recommends a vote "FOR" citing these oversight and independence safeguards.

3. 3

   Advisory Vote on Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   This management-sponsored advisory resolution requests shareholder approval of the Company’s executive compensation disclosure and arrangements for named executive officers (the ‘say-on-pay’ vote). The proposal is non-binding but signals shareholder sentiment to the Compensation Committee and Board. Management argues that the compensation program emphasizes pay-for-performance with a high proportion of at-risk compensation (e.g., 93% of CEO target, 83% for other NEOs), ties short-term bonuses to R&D and milestone-based goals, and uses a mix of options, RSUs, and PSUs for long-term incentives to align management and shareholder interests. The Board will consider the advisory vote results when making future compensation decisions and has a prior history of strong shareholder support (~85.7% in 2025). The Board recommends a vote FOR.

Upcoming shareholder meetings at Structure Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Structure Therapeutics Inc 2026 annual meeting?

Structure Therapeutics Inc (GPCR) holds its 2026 annual shareholder meeting on Wednesday, June 17, 2026.

What is the record date for the Structure Therapeutics Inc 2026 meeting?

The record date for the Structure Therapeutics Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Structure Therapeutics Inc's 2026 meeting?

The board is presenting 3 director nominees at the Structure Therapeutics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Structure Therapeutics Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Structure Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.